- Home
- JLS vs MRK Comparison
JLS vs MRK Comparison
Compare JLS & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLS | MRK |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.4M | 260.2B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JLS | MRK |
|---|---|---|
| Price | $18.19 | $106.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $111.93 |
| AVG Volume (30 Days) | 26.6K | ★ 14.8M |
| Earning Date | 01-01-0001 | 02-03-2026 |
| Dividend Yield | ★ 9.33% | 3.19% |
| EPS Growth | N/A | ★ 58.08 |
| EPS | N/A | ★ 7.56 |
| Revenue | N/A | ★ $64,235,000,000.00 |
| Revenue This Year | N/A | $1.98 |
| Revenue Next Year | N/A | $4.94 |
| P/E Ratio | ★ N/A | $14.09 |
| Revenue Growth | N/A | ★ 1.68 |
| 52 Week Low | $15.48 | $73.31 |
| 52 Week High | $17.97 | $106.95 |
Technical Indicators
Market Signals| Indicator | JLS | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 36.84 | 70.67 |
| Support Level | $18.15 | $96.79 |
| Resistance Level | $18.46 | $100.94 |
| Average True Range (ATR) | 0.22 | 2.34 |
| MACD | -0.01 | 0.33 |
| Stochastic Oscillator | 8.93 | 96.13 |
Price Performance
Historical ComparisonAbout JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).